Resources
Practical, sourced guidance for prescribing providers and compounding pharmacies: peptides, GLP-1s, 503A vs 503B, sourcing, and growth.
FDA’s July 2026 peptide advisory panel, the EVEXIAS Category 2 lawsuit, and RFK Jr’s influence, explained for clinicians and compounding pharmacies deciding how to act.
For ProvidersWorried a compounded GLP-1 line is a compliance landmine? Learn how to prescribe compounded semaglutide in 2026: the 503A path, documentation, and safe sourcing.
For ProvidersA BPC-157 prescribing guide for clinicians: what the 2026 reclassification changed, why Category 2 removal is not FDA approval, and how to source compliantly.
For PharmaciesHow to get more prescriptions for your compounding pharmacy without a rep network: win provider referrals, keep your margin, and turn verified quality into demand.
For ProvidersA practical guide to how to add peptide therapy to your practice: the compliance, sourcing, and fulfillment hurdles, and how a verified marketplace removes them.
For PharmaciesThe difference between 503A and 503B compounding pharmacies: oversight, office stock, cGMP vs USP, and where peptides and GLP-1s land in 2026, from primary FDA sources.
For PharmaciesA 2026 guide to compounding pharmacy marketing: what actually drives patient search and prescriber referrals, how to stay compliant, and how to grow without a sales team.